NEWS OUT...IT WORKS!!! Cellceutix Reports In Vivo Tumor

New Post Public Reply Private Reply Replies (2) Message Board

buccaneer1961 Dynabolic #6880

Jan 24, 2013 at 2:31 AM

NEWS OUT...IT WORKS!!! Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer

BEVERLY, MA – January 24, 2013-- Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has received results from in vivo studies conducted at Beth Israel Deaconess Medical Center (“BIDMC”). Cellceutix had earlier reported that they entered into an agreement with BIDMC, a teaching hospital of Harvard Medical School, on an innovative research project with Kevetrin™, the Company’s flagship anti-cancer drug. BIDMC wishes to exploit the nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.

Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we've used in which actual tumor shrinkage is noted.”

Per protocol, Cellceutix has formally notified BIDMC that it has a strong interest in further collaborative efforts to develop combination treatments with Kevetrin and multikinase VEGF receptor antagonists, particularly VEGFR2 inhibitors. Cellceutix has provided the requested information that will be used to investigate a Specialized Programs of Research Excellence (SPORE) grant for a phase 2 clinical study.

Renal cell carcinoma is the most common type of kidney cancer in adults. BIDMC is the lead recipient of the prestigious National Cancer Institute-funded kidney cancer SPORE grant.

About SPORE
In 1992, the National Cancer Institute (NCI) established the Specialized Programs of Research Excellence (SPOREs), specialized cancer center grants to promote and speed up the exchange between interdisciplinary research in the laboratory to the treatment of patients in the clinical care setting.

SPORE programs allow laboratory and clinical scientists to work collaboratively to plan, design, and implement research programs with the greatest potential to impact cancer prevention, detection, diagnosis and treatment.

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

The clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Cellceutix Corp.
Leo Ehrlich
(978) 236-8717

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SRG DocketWatch: Tracking FCC Docs in Real-Time

I'll admit it—sometimes the FCC moves like molasses uphill. But keeping track of what they're up to? That's where the real challenge lies. Summit Ridge Group has tossed a lifeline for anyone who's got skin in the game with their new service, SRG DocketWatch. Why SRG DocketWatch Hits the Mark If you're poking your head into more than a few of those 21,000 FCC...

XPENG Eyes South Korea Entry with Industry Veteran

A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...

New Study Exposes Grim Reality for Moderate Aortic Stenosis

Uncovering the Stark Truth of Moderate Aortic Stenosis When you hear about heart issues, the last thing you want to think about is moderate anything. But this study out of San Diego sure throws a wrench in how we size up moderate aortic stenosis. Turns out these patients aren't just in a holding pattern—they're facing some serious storm clouds. High Stakes for...

PG&E, Edison Push Liability Cap Amid Firestorm

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

SecureSpace Expands into Dallas-Fort Worth Market

A New Player in Dallas-Fort Worth SecureSpace Self Storage has stormed into the Dallas-Fort Worth area, ushering in a sizeable expansion with four brand-new locations. This move is big news for the self-storage operator, marking its very first foray into the Texan market and boosting its nationwide presence past that century mark – 101 stores and counting. Call it a...

Vanity Fair Lingerie Reveals New Smoothing Bra

A Bra Revolution or Just Another Launch? I'll admit it, lingerie isn't the usual breakfast discussion for me, but Vanity Fair Lingerie's move with their new Flawlessly Smooth™ Bra piqued my interest. Announced in Bowling Green, Kentucky, on November 2, 2026, and set against the lavish backdrop of an upcoming New York City event cohosted by Cosmopolitan, it's less about...

China-CEEC Forum Sparks Robust SME Partnerships

There’s a fresh buzz around Cangzhou's efforts to galvanize business opportunities between China and Central and Eastern Europe. The 7th China-CEEC SME Forum, kicking off in this city of Hebei Province, isn’t just another meeting of the minds. Nope, it’s like a marketplace thrown into overdrive—where AI strategies and logistics are shaping up to be the star...

Wincomm & Portwell Unveil Medical AI Tech at MEDICA 2026

MEDICA 2026: Wincomm and Portwell Join Forces November's got one heck of an event lined up with MEDICA 2026, where Wincomm and Portwell are teaming up to showcase what they've got up their sleeves in medical AI computing. This whole shebang runs from November 16 to 19, with their setup in Hall 12, Stand C76, Düsseldorf, Germany. But why should investors care? Because...

Dun & Bradstreet's Merger Sparks Legal Showdown

Shake-Up in Investor Circles Over D&B Class Action Lemme tell ya, Dun & Bradstreet Holdings (NYSE:DNB)—that name is echoing through courtrooms these days. It's like watching an old time Wall Street brawler go a few rounds with a heavyweight. Investors better sit tight because we've got a class action cooked up, and the lead plaintiff deadline smacks us in the face on...

Mind Meets Soul: Neuroscience and Spiritual Pathways

The Brain, Stress, and Spiritual Practices Ever tried to meditate and wondered if it actually does a number on your mind? Well, here comes Dr. Helen Lavretsky, who’s delving into the nitty-gritty of what happens up there when stress hits and spirituality steps in. This session on November 10 is bound to be a humdinger in the realm of science-meets-spirit. If you've ever...